Viloxazine trial for preschool kids with ADHD
Part of Mental health clinical trials.
This study tests whether viloxazine extended-release can reduce ADHD symptoms in children ages 4–5. It also checks safety in preschool-age kids, including heart and nervous-system side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is 4 years 0 months to 5 years 9 months old at screening and is generally healthy.
- A parent/guardian can sign consent to join the study.
- Your child has a main diagnosis of ADHD, confirmed by structured clinical interviews.
- Your child’s ADHD symptom severity is high on rating scales at screening and start of the study (Visit 2).
- Your child participates in a structured group setting outside the home at least 2 days per week.
- Your child is not starting new behavior therapy in the last 30 days and does not plan major changes during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new non-stimulant medication called viloxazine for children and teens with ADHD. It aims to see if it helps reduce symptoms like inattention and hyperactivity.
This study tests a long-acting form of the medicine clonidine (called Onyda XR) to see if it safely reduces symptoms of ADHD and oppositional defiant disorder in children. Children who join will take the study medicine or a placebo for a set period, and their symptoms will be tracked.
This study tests a medication called Foquest to see if it helps older adults with ADHD. It aims to improve attention and reduce hyperactivity or impulsivity in people aged 65 and above.
This trial tests an early intervention program for young children (about ages 3 to 5) with clinically significant attention and behavior symptoms. It may help by targeting ADHD-related difficulties seen at home and school.
This trial tests starting a new medication (Methylphenidate or Guanfacine) in young children with moderate or severe ADHD to see how well it works and if it’s safe.
This study tests an investigational medication for adults with attention deficit hyperactivity disorder (ADHD). It aims to see if this new drug helps reduce ADHD symptoms compared to a placebo.
Hear when a new ADHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.